Sort

Search

Search Bar
08/02/2022 Non-invasive oxygenation support in acutely hypoxemic COVID-19 patients admitted to the ICU: a multicenter observational retrospective study
Wendel-Garcia, PD, Mas, A, Gonzalez-Isern, C, Ferrer, R, Manez, R, Masclans, JR, Sandoval, E, Vera, P, Trenado, J, Fernandez, R, Sirvent, JM, Martinez, M, Ibarz, M, Garro, P, Lopera, JL, Bodi, M, Yebenes-Reyes, JC, Triginer, C, Vallverdu, I, Baro, A, Bodi, F, Saludes, P, Valencia, M, Roche-Campo, F, Huerta, A, Cambra, FJ, Barbera, C, Echevarria, J, Penuelas, O, Mancebo, J, UCIsCAT Study Grp. Non-invasive oxygenation support in acutely hypoxemic COVID-19 patients admitted to the ICU: a multicenter observational retrospective study. CRITICAL CARE. 2022; 26(1)DOI:10.1186/s13054-022-03905-5. PMID:35135588. IF:15.100(Q1/2D).
08/02/2022 Booster effect after SARS-CoV-2 vaccination in immunocompromised hematology patients with prior COVID-19
Pinana, JL, Garcia-Sanz, R, Martino, R, Garcia-Rao, M, Martin-Martin, GA, Risco-Galvez, I, Tormo, M, Martinez-Barranco, P, Marcos-Corrales, S, Calabuig, M, Conesa, V, Teruel, A, Ruiz-Perez, S, Solano, C, Navarro, D, Cedillo, A, Sureda, A. Booster effect after SARS-CoV-2 vaccination in immunocompromised hematology patients with prior COVID-19. Blood Advances. 2022; 6(3)DOI:10.1182/bloodadvances.2021006326. PMID:34905620. IF:7.500(Q1/2D).
08/02/2022 Prognostic impact of DNMT3A mutation in acute myeloid leukemia with mutated NPM1
Onate, G, Bataller, A, Garrido, A, Hoyos, M, Arnan, M, Vives, S, Coll, R, Tormo, M, Sampol, A, Escoda, L, Salamero, O, Garcia, A, Bargay, J, Aljarilla, A, Nomdedeu, JF, Esteve, J, Sierra, J, Pratcorona, M. Prognostic impact of DNMT3A mutation in acute myeloid leukemia with mutated NPM1. Blood Advances. 2022; 6(3)DOI:10.1182/bloodadvances.2020004136. PMID:34516636. IF:7.500(Q1/2D).
08/02/2022 Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML
Menghrajani, K, Gomez-Arteaga, A, Madero-Marroquin, R, Zhang, MJ, Bo-Subait, K, Sanchez, J, Wang, HL, Aljurf, M, Assal, A, Bacher, VU, Badawy, SM, Bejanyan, N, Bhatt, VR, Bredeson, C, Byrne, M, Castillo, P, Cerny, J, Chhabra, S, Ciurea, SO, DeFilipp, Z, Farhadfar, N, Gadalla, S, Gale, RP, Ganguly, S, Gowda, L, Grunwald, MR, Hashmi, S, Hildebrandt, G, Kanakry, CG, Kansagra, A, Khimani, F, Krem, M, Lazarus, H, Liu, HT, Martino, R, Michelis, FV, Nathan, S, Nishihori, T, Olsson, R, Reshef, R, Rizzieri, D, Rowe, JM, Savani, BN, Seo, S, Sharma, A, Solh, M, Ustun, C, Verdonck, LF, Hourigan, C, Sandmaier, B, Litzow, M, Kebriaei, P, Weisdorf, D, Zhang, YM, Tallman, MS, Saber, W. Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML. Blood Advances. 2022; 6(3)DOI:10.1182/bloodadvances.2021004881. PMID:34551064. IF:7.500(Q1/2D).